Cross-reacting Escherichia coli strains Easter and 89 and Bacillus pumilis fed to newborn rabbits and E. coli fed to adult rhesus monkeys did not exert untoward reactions. The E. coli regularly colonized the newborns' intestinal tract from 1 to 7 weeks. High doses of E. coli were necessary to colonize adult primates. Colonization occurred in fewer newborn rabbits and lasted only 1 to 3 weeks with B. pumilis. Colonized newborn rabbits and adult rhesus had an active Haemophilus influenzae type b (HITB) immune response. In the rabbit, colonization resulted in accelerated induction of immunoglobulin (Ig) M-, IgA-, and IgG-producing cells in the spleen, mesenteric lymph nodes, and Peyer's patches after HITB challenge. E. coli-fed and control newborn primates were naturally colonized with nasopharyngeal and enteric cross-reacting bacteria and both groups rapidly developed HITB antibodies in the absence of the homologous organisms. Human newborn stool cultures, taken at the time of discharge from the nursery, showed a 0.9% carriage rate for cross-reacting E. coli. These "carrier" infants acquired HITB antibodies more rapidly than their age-matched "noncarrier" controls.
Haemophilus influenzae type b (HITB) is the leading cause of endemic bacterial meningitis and an etiologic agent of other serious infectious diseases in the United States and in many other countries (12, 13, 20, 23, 25, 26, 35, 39, [43] [44] [45] . Because they have lost their transplacentally acquired antibodies and have not yet developed antibody synthesis, individuals older than 3 months and younger than 6 years constitute the most susceptible age group (2, 5, 6, 12, 13, 26, 31, 33, 38) . The specificity of these protective serum antibodies is mostly anticapsular (2, 3, 5, 6, 28, 29, 31, '.3, 35, 38) .
The wide prevalence of anticapsular antibodies in the normal adult population is difficult to explain by asymptomatic carriage of the homologous organism since its occurrence in normal infants and children is low and it is rarely found in adults (10, 12, 15, 35, 42, 44) . In addition, a similar age-related development of anticapsular antibodies was observed in laboratory rabbits and primates without detection of HITB (37) .
Utilizing the antiserum agar technique (10, 27 ), Escherichia coli and several gram-positive bacteria containing polyribitol phosphate as their cell wall teichoic acid were found to cross-react with the capsular polysaccharide of HITB (7, 16, 36) . In an earlier report it was found that feeding of two cross-reacting E. coli strains accelerated the formation of HITB antibodies in newborn laboratory rabbits (24) . At 8 weeks of age the fed animals had higher levels of HITB antibodies than controls. An active heteroimmune response was shown by the higher serum anticapsular antibodies of the E. coli-fed animals after challenge with living HITB organisms. These findings suggested that immunization against HITB diseases in humans could be achieved by neonatal feeding of enteric nonpathogenic, cross-reacting bacteria. Accordingly, more detailed and comparative studies of the relation between these organisms as inhabitants of the gastrointestinal tract and the development of HITB antibodies in laboratory rabbits, rhesus monkeys, and human infants were undertaken.
(These data were presented in preliminary form to the Society for Pediatric Research, San Francisco, Calif., May 1973, and at the 4th International Convocation on Immunology, Buffalo, N.Y., June 1974.) MATERIALS AND METHODS Bacteria. The antigenic and immunogenic properties of the cross-reacting E. coli 075:K100:H5, strains Easter and 89, and Bacillus pumilis (Sh-18), media, and growth conditions, and intravenous challenge with HITB (strain Rab) have been described (7, 36) . The cross-reacting antigen, previously designated Kf147, has been assigned the nomenclature K100 and the W.H.O. test strain is f147/51.
Antiserum agar. The preparation of the antiserum agar with tryptic soy broth (Difco) for stool cultures and of Levinthal media (BHI, Difco) for nasopharyngeal cultures utilizing burro HITB antiserum has been described (7, 36) .
Animals. Newborn hybrid rabbits were raised and maintained in our laboratory. Newborn rhesus (Macacca mulatta) raised at the Primate Research Center, University of California, Davis, were maintained with their mothers throughout the experiment. The E. coli-fed and saline-fed (controls) animals were housed separately. The adult primates (1 to 2 years) fed strain Easter were housed in separate rooms at the Food and Drug Administration and were kept two to three animals per cage. The primates fed strain 89 ranged from 2 to 3 years of age and were housed in individual cages in the same room at the National Institute of Child Health and Human Development. The organisms for feeding were prepared from a 4-to 5-h culture. The animals were fed 1 g of sodium bicarbonate before feeding of the bacteria to prevent acid denaturation during their passage through the stomach (11, 32) .
Antibody assay. The HITB capsular polysaccharide and its tyraminated derivative were prepared for radioimmunoassay of anticapsular antibodies as described (15, 31) . The sensitivity of the assay was 0.05 gg of antibodies per ml and the reproducibility was -12% in the range of 0.05 to 1.8 ,ug/ml. Sera withdrawn for routine laboratory assays from infants attending the outpatient department of Charlotte Memorial Hospital, and maternal and cord sera to be discarded from the blood bank of Charlotte Memorial Hospital and the Jacobi Hospital of Albert Einstein College of Medicine, Bronx, N.Y., were used as controls. Sixteen of the 23 carriers were available for continued study and serum HITB antibodies were assayed at various intervals up to 2 years. Fifteen of the 16 carriers had detectable HITB antibodies on all occasions. In contrast, 16 of 52 (30%) infants and children, ages 2 to 24 months, did not have detectable HITB antibodies. It should be emphasized that controls were not cultured for HITB or cross-reacting E. coli or other organisms during the study. Their carriage of cross-reacting E. coli is expected to be 1% as in the general population. The difference between the two groups is statistically significant (Yates corrected chi square = 17.11, P < 0.005). It is of interest that 4 of the 16 carriers had no detectable cord HITB antibodies. At age 2 to 4 months, their serum HITB antibodies were 0.34, 0.22, 0.32, and 0.21 ,g/ml, suggesting active synthesis at this age.
Plaque-forming cells (PFCs

DISCUSSION
The concept that "natural" antibodies and, hence, protective immunity to invasive diseases caused by HITB (and possibly to other encapsulated bacteria) may be due to antigenic stimulation by enteric cross-reacting bacteria has gained support from our findings (10, 24, 30, 35) . Most adult rabbits and primates (M. mulatta) have serum anticapsular antibodies without detectable carriage of HITB (24) . Rabbits were shown to have a variety of cross-reacting bacteria including E. coli, bacilli, staphylococci, and various gram-negative organisms. The rapid development of anticapsular antibodies in neonatal rhesus was related to the frequent finding of cross-reacting bacteria in the absence of demonstrable HITB in these animals. In all fed and control animals, stool and nasopharyngeal S. aureus was detected in at least one sample. S. aureus, coagulase positive, contains polyribitol phosphate as a component of its cell wall teichoic acid and has been shown to induce HITB capsular antibodies in rabbits and burros after intravenous injection (7). Obviously, S. aureus, coagulase positive, fed to newborns is not a suitable organism for consideration as an immunizing agent to HITB.
Colonization with cross-reacting E. coli was observed in 0.9% of normal human newborns at 4 days of age. As observed with the animals deliberately fed the cross-reacting bacteria at birth, this natural colonization was transient and seemed to have no effect upon the health and development of the newborn. Thus, consistent with the in vitro assays showing no enteropathogenicity characteristics, naturally occurring or deliberate colonization with high concentrations of these bacteria seems to be harmless. In experiments to be published we have found that stool cultures from healthy adults yield the cross-reacting E. coli 075:K100:H5 with the same frequency as observed in the newborns. (1, 9) .
A comparison between the two cross-reacting E. coli and B. pumilus as potential immunogens reveals differences: the highest rate of colonization was induced by E. coli Easter and the lowest with Sh-18. However, the highest levels as well as the widest range of anti-type b. antibodies were observed in the Sh-18 animals. Further studies with combinations of those organisms are planned to determine the most effective heteroimmunogen.
Spontaneous acquisition of cross-reacting bacteria is a probable mechanism for synthesis of natural and protective antibodies to at least several pyogenic bacteria. Gastrointestinal colonization of human newborns by E. coli 083 has been accomplished by neonatal feeding without ill effect by Lodinova et al. (21, 22) . Protective immunity to pneumococci was induced by feeding the homologous organism lo rats (34) . Heteroimmunization to the human blood group B substance has been achieved by feeding of cross-reacting E. coli to human adults and infants (19, 40) . This colonization resulted in the synthesis of serum and intestinal antiantibodies to the E. coli 0 antigen earlier than in age-matched controls. The conditions for feeding and colonizing adult human volunteers with pathogenic E. coli have been characterized (11) . This information forms the basis for feeding cross-reacting E. coli to assay their heteroimmunogenicity for HITB in adult humans. Other enteric nonpathogenic bacteria with crossreacting antigens to pathogenic encapsulated bacteria have been isolated and characterized. Use of these cross-reacting bacteria to feed and colonize human newborns may be a general method for preventative immunization against invasive bacterial diseases (19, 21, 22, 34, 35) .
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